Basic of Presentation (Tables)

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Significant Intercompany Transactions

All significant intercompany transactions have been eliminated. Details of the Company’s subsidiaries are as follows:

Name	Date of incorporation or establishment	Place of incorporation (or establishment) /operation	Percentage of ownership as of December 31, 2018			Percentage of ownership as of December 31, 2017			Principal activities
Sinovac Biotech (Hong Kong) Ltd.    (“Sinovac Hong Kong”)	October 2008	Hong Kong		100	%		100	%	Investment holding company
Sinovac Biotech Co., Ltd. (“Sinovac    Beijing”)	April 2001	People’s Republic of China (“PRC”)		73.09	%		73.09	%	Research and development, production and sales of vaccine products
Sinovac Research & Development    Co., Ltd. (“Sinovac R&D”)	May 2009	PRC		100	%		100	%	Research and development of vaccine products
Sinovac (Dalian) Vaccine Technology    Co., Ltd.(“Sinovac Dalian”)	January 2010	PRC		67.86	%		67.86	%	Research and development, production and sales of vaccine products
Sinovac Biomed Co., Ltd.	April 2015	PRC		100	%		100	%	Distribution of vaccine products